Mon, Dec 22, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Alternative Market Briefing

China Investment Corporation said to be in talks with large U.S. hedge funds, former University of Toronto Asset Management staff the gatekeepers?

Tuesday, July 07, 2009

From Matthias Knab, Opalesque Europe:

According to information obtained by Opalesque, global hedge fund managers rushed into Beijing for chances to meet with staff from China Investment Corporation (CIC), which said it would invest billions dollars in the absolute return field. Most of those money managers are from New York, London, Chicago, San Francisco and Connecticut, etc.

CIC’s activities are rather secretive - their officials usually don't appear in public events but rather use private connections. Hedge funds around the world are struggling to find ways to access CIC. The most common questions circle about the standards and requirements on mandates by the China fund.

At Opalesque, I have personally received quite a few emails bluntly asking me for "an introduction". In fact, we do have relationships to the CIC and many others, but obviously an email coming out of nowhere from a stranger asking "hey, know anyone at CIC?" isn't maybe the most promising approach.

According to some sources, CIC had been in talks with several large US hedge fund managers since last summer. Beside the investments in Blackstone Group’s hedge funds, the names mentioned include Citadel Investment Group, D.E. Shaw, Paulson & Co, Renaissance Technologies, SAC Capital and Tudor Investment Group.

A fund of fund manager reported that Felix Chee, who acts as senior adviser of CIC, had hired "lots" of former colleagues from the University of Toronto Asset Management Cor......................

To view our full article Click here

Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Investing - Big hedge funds win again on PetSmart, Riverbed, RBS sells real estate loans to hedge fund Cerberus, Talisman energy speculation: Which hedge funds could benefit?[more]

    Big hedge funds win again on PetSmart, Riverbed From CNBC.com: Another week, another set of wins for activist investors. On Sunday, pet supply retailer PetSmart agreed to the largest leveraged buyout of the year at $8.7 billion. Hedge fund firm JANA Partners had been pushing for a sale a

  2. Outlook - Hedge fund manager who remembers 1998 rout says prepare for pain, Bond guru Bill Gross predicts U.S. economic growth to dip to 2%[more]

    Hedge fund manager who remembers 1998 rout says prepare for pain From Bloomberg.com: Stephen Jen landed in Hong Kong in early January 1997 as Morgan Stanley’s newly minted exchange-rate strategist for Asia. He was soon working around the clock when investors began targeting the region’s

  3. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  4. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  5. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for